Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 115,077 | 174,927 | 139,376 | 67,669 | 47,989 |
| Marketable Securities | 676,479 | 581,386 | 537,562 | 177,351 | 160,912 |
| Receivables | 54,798 | 61,047 | 58,096 | 52,392 | 42,831 |
| Inventories | 13,266 | 9,126 | 11,900 | 15,489 | 14,614 |
| Other current assets | 5,795 | 5,785 | 6,986 | 40,044 | 42,970 |
| TOTAL | $865,415 | $832,271 | $753,920 | $352,945 | $309,316 |
| Non-Current Assets | |||||
| PPE Net | N/A | N/A | 3,466 | 3,632 | 3,623 |
| Investments And Advances | 312,821 | 364,828 | 355,053 | 10,908 | 10,908 |
| Intangibles | 318,882 | 326,979 | 335,076 | 351,674 | 359,932 |
| Other Non-Current Assets | 34,987 | 36,559 | 29,257 | 229,445 | 221,656 |
| TOTAL | $666,690 | $728,366 | $722,852 | $595,659 | $596,119 |
| Total Assets | $1,532,105 | $1,560,637 | $1,476,772 | $948,604 | $905,435 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 5,264 | 3,238 | 3,679 | 8,584 | 5,366 |
| Accrued Expenses | 31,845 | 31,453 | 24,084 | 17,464 | 23,537 |
| Other current liabilities | 577 | 422 | 403 | 37,157 | 26,993 |
| TOTAL | $40,667 | $37,447 | $30,539 | $64,734 | $58,683 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | N/A | N/A | 111 | 101 |
| Other Non-Current Liabilities | 471,502 | 469,959 | 473,389 | 23,095 | 21,839 |
| TOTAL | $494,116 | $505,978 | $496,062 | $55,341 | $51,218 |
| Total Liabilities | $534,783 | $543,425 | $526,601 | $120,075 | $109,901 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 20,041 | 19,941 | 19,682 | 19,597 | 19,294 |
| Common Shares | 20 | 20 | 20 | 20 | 20 |
| Retained earnings | 594,743 | 608,088 | 578,215 | 461,380 | 456,533 |
| Other shareholders' equity | 5,390 | 8,455 | 9,322 | 8,494 | -1,563 |
| TOTAL | $997,322 | $1,017,212 | $950,171 | $828,529 | $795,534 |
| Total Liabilities And Equity | $1,532,105 | $1,560,637 | $1,476,772 | $948,604 | $905,435 |